IMDZ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMDZ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Immune Design's Revenue for the three months ended in Dec. 2018 was $0.48 Mil. Immune Design's average Accounts Receivable for the three months ended in Dec. 2018 was $0.74 Mil. Hence, Immune Design's Receivables Turnover for the three months ended in Dec. 2018 was 0.64.
The historical data trend for Immune Design's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immune Design Annual Data | ||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||
Receivables Turnover | Get a 7-Day Free Trial | 6.25 | 6.46 | 17.81 | 12.36 | 3.25 |
Immune Design Quarterly Data | ||||||||||||||||||||
Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | |
Receivables Turnover | Get a 7-Day Free Trial | 0.83 | 1.02 | 1.51 | 0.64 | 0.64 |
For the Biotechnology subindustry, Immune Design's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Immune Design's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Immune Design's Receivables Turnover falls into.
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
Immune Design's Receivables Turnover for the fiscal year that ended in Dec. 2018 is calculated as
Receivables Turnover (A: Dec. 2018 ) | |||||||
= | Revenue | / | Average Total Inventories | ||||
= | Revenue (A: Dec. 2018 ) | / ( | (Accounts Receivable (A: Dec. 2017 ) | + | Accounts Receivable (A: Dec. 2018 )) | / | count ) |
= | 2.196 | / ( | (0.647 | + | 0.705) | / | 2 ) |
= | 2.196 | / | 0.676 | ||||
= | 3.25 |
Immune Design's Receivables Turnover for the quarter that ended in Dec. 2018 is calculated as
Receivables Turnover (Q: Dec. 2018 ) | |||||||
= | Revenue | / | Average Total Inventories | ||||
= | Revenue (Q: Dec. 2018 ) | / ( | (Accounts Receivable (Q: Sep. 2018 ) | + | Accounts Receivable (Q: Dec. 2018 )) | / | count ) |
= | 0.476 | / ( | (0.78 | + | 0.705) | / | 2 ) |
= | 0.476 | / | 0.7425 | ||||
= | 0.64 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immune Design (NAS:IMDZ) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Thank you for viewing the detailed overview of Immune Design's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
William R Ringo | director | |
David Baltimore | director | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Edward Penhoet | director | ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111 |
Susan L. Kelley | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Carlos V Paya | director, officer: President and CEO | C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102 |
David V Goeddel | 10 percent owner, other: Managing Partner | C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Column Group Ii, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Peter Svennilson | 10 percent owner, other: Managing Partner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Tim Kutzkey | 10 percent owner, other: Managing Partner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Column Group Ii Gp, Lp | 10 percent owner, other: General Partner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Ponoi Capital, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Ponoi Management, Llc | 10 percent owner, other: General Partner | 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129 |
Column Group L P | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Column Group Gp, Lp | 10 percent owner, other: General Partner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Franklin M Berger | director | 1000 MARINA BLVD, STE 200, BRISBANE CA 94005 |
From GuruFocus
By Marketwired Marketwired • 12-02-2018
By Marketwired Marketwired • 07-25-2018
By Marketwired Marketwired • 04-25-2018
By PRNewswire PRNewswire • 02-21-2019
By Kyle Ferguson Kyle Ferguson • 10-03-2016
By Marketwired Marketwired • 10-30-2018
By GlobeNewswire GlobeNewswire • 12-02-2018
By Tiziano Frateschi Tiziano Frateschi • 10-04-2016
By Marketwired Marketwired • 11-09-2018
By PRNewswire PRNewswire • 02-21-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.